On August 22, 2024, the China Association of In-Vitro Diagnostics (CAIVD) welcomed a delegation from the Korea In Vitro Diagnostics Association (KIVDA) for a strategic visit aimed at strengthening collaboration between the two nations’ IVD industries.

Thermo Fisher Scientific, the world leader in serving science, will significantly expand local operations in Indonesia with the opening of its first official office. The inauguration of the new facility in Jakarta is scheduled for April, signifying a key milestone as the company transitions from its current representative office to a larger workspace.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

On July 27, the Indonesia-China Healthcare and Biotechnology Investment Forum, co-sponsored by the Embassy of the Republic of Indonesia in China and the China Committee of the Indonesian Chamber of Commerce and Industry, was held in Chengdu.

Beijing Hotgen Biotech Co., Ltd（688068.SH）released an announcement on July 6, the company intends to use its own funds together with Qingdao Chuangjing Private Equity Fund Management Co., Hangzhou Bioer Technology Co.,Ltd, Anhui Yaoan Investment Group Co. and Shaoxing Guochuang Zhende Medical (603301) Industry Phase I Equity Investment Partnership (Limited Partnership) co-finance and participate in the investment in Tristar Conrad.

Evident Corporation announced that it has been acquired by private equity firm Bain Capital Private Equity from Olympus Corporation pursuant to the definitive agreement signed on August 29, 2022.

To further promote the construction of a Healthy China planning a new "construction plan", the State Council issued the "Healthy China Initiative (2019-2030)", the program focuses on the current major health problems and factors affecting the two core disease prevention and health promotion.

Cue Health Inc., a healthcare technology company, reported financial results for the fourth quarter and full-year 2022.

On December 28,Shanghai Universal Biotech Co.,Ltd. was listed on the Shenzhen Stock Exchange (SZSE) ChiNext, stock code: 301166. The issue price is 86.06 yuan/share, and the opening price is 92 yuan/share.